KP
Kwality Pharmaceuticals Ltd (KPL)
₹4,128.40
Mkt cap
₹4,284 Cr
P/E ratio
44.40
P/B
11.10
Div yield
0.00%
ROE
22.60%
ROCE
24.10%
EPS (TTM)
₹92.98
Book value
₹372
52W range
1,561–4,299
Sector
Healthcare
Price history
Previous close
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products [1]
NSE KPLBSE 539997
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−3.97% from high₹4,128
₹1,561+164.47% from low₹4,299
Current
₹4,128.40
Prev close
₹4,286.60
Day
−3.69%
Price performance
1D
−3.72%
1W
+7.96%
1M
+14.06%
3M
+13.68%
6M
+97.75%
1Y
—
YTD
+148.31%
Financials
Revenue, profit & margin
P/E ratio
44.4×
KPL is 37% above the sector median of 32.5×
KPL44.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 | 111 | 123 | 157 | 162 | 181 | |
| YoY Sales growth | +25% | +39% | +34% | +19% | +29% | +8% | +26% | +39% | +23% | +46% | +36% | +46% | +63% | |
| Expenses | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 | 86 | 93 | 118 | 121 | 131 | |
| Operating Profit | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 | 25 | 30 | 39 | 41 | 50 | |
| OPM % | 22% | 21% | 22% | 22% | 22% | 21% | 22% | 22% | 23% | 24% | 25% | 25% | 27% | |
| Other Income | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 | 1 | -0 | 1 | 1 | 1 | |
| Interest | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 3 | |
| Depreciation | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | |
| Profit before tax | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 | 18 | 22 | 32 | 34 | 42 | |
| Tax % | 24% | 21% | 29% | 25% | 33% | 25% | 24% | 30% | 23% | 28% | 20% | 25% | 31% | |
| Net Profit | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 | 14 | 16 | 25 | 26 | 29 | |
| EPS in Rs | 6.01 | 7.41 | 4.20 | 8.06 | 8.16 | 8.22 | 13.96 | 11.50 | 13.61 | 15.43 | 24.38 | 24.69 | 27.98 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202654.86%Promoter
Promoters54.86%
FIIs2.50%0.63
DIIs1.07%0.51
Public41.57%0.12
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Kwality Pharma | ₹4,128.40 | 44.37 | 4,284 | 0.00% | 29 | +105.59% | 181 | +63.19% | 24.08% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports11
Concall transcripts17
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Nov - Newspaper Publication of Unaudited Financial Results for the quarter and half year ended September 30, 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript 16 NovAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 Nov - Audio recording of November 9, 2026 investor earnings call uploaded to company website.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 14 Nov - Audio recording of November 9, 2026 earnings call uploaded for Q2 and half-year FY2026 results.Announcement under Regulation 30 (LODR)-Investor Presentation 12 Nov - Investor Presentation for the quarter and half year ended unaudited financial results for 30-09-2026






